AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Discussion with House and Senate offices on opioid addiction and the Mainstreaming Addiction Treatment Act of 2021 (H.R. 1384/S.445). Met with House and Senate to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Met with White House to discuss issues related to drug pricing, drug shortages, and the drug supply chain. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House offices, Senate offices, and agencies. Patient access to: pharmacist provided vaccinations COVID/flu/pediatric illnesses, COVID-19 testing, Emergency HIV prophylaxis, Initiation of oral antivirals for flu/COVID, Buprenorphine, Diabetes monitoring and management, Other pharmacist services authorized under state law.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHERINE GAYNOR New | — |
| NICHOLAS GENTILE New | — |
| DOUGLAS HUYNH | — |
| THOMAS KRAUS | — |
| JILLANNE SCHULTE | — |
Medicare/Medicaid MMM
Communicate with the Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, PBM transparency, pharmacy residency audit, and scope of practice. Discussion with House and Senate about increased prescription drug pricing, specifically on the Ensuring Innovation Act (S.415) and the Advancing Education on Biosimilars Act (s. 164). Communication on Direct and Indirect remuneration fees (DIR) under Medicare Part D and Medicare rebate reform. Communication with CMS and Congressional Offices on pharmacy residency programs audits. Communication with CMS, White House Offices, and Congressional Offices on Reimbursement through Medicare Part B. Discussed COVID-19 response recommendations, including pharmacist provision of testing and vaccination, with House and Senate Offices, and HHS. Discussed telehealth reimbursement and virtual supervision flexibilities for pharmacist services with CMS. Discussed continuation of PREP Act allowances with HHS. Discussion with House and Senate Offices about the Pharmacist and Medically Underserved Areas Enhancement Act (H.R. 2759/S. 1362)
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHERINE GAYNOR New | — |
| NICHOLAS GENTILE New | — |
| DOUGLAS HUYNH | — |
| THOMAS KRAUS | — |
| JILLANNE SCHULTE | — |
Pharmacy PHA
Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its subagencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Contact FDA concerning the practice of White Bagging and Brown Bagging patient medications. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHERINE GAYNOR New | — |
| NICHOLAS GENTILE New | — |
| DOUGLAS HUYNH | — |
| THOMAS KRAUS | — |
| JILLANNE SCHULTE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.